These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 10532841)
1. [Guidelines for prescription drugs; special interests are counterproductive]. Kirsten WD Internist (Berl); 1999 Aug; 40(8):224-5. PubMed ID: 10532841 [No Abstract] [Full Text] [Related]
2. [Psychopharmacological regulations. Results and commentary to the report on drug regulations 2002]. Fritze J Nervenarzt; 2003 Mar; 74(3):301-6. PubMed ID: 12722759 [No Abstract] [Full Text] [Related]
3. The pharmaceutical market and prescription drugs in the Federal Republic of Germany: cross-national comparisons. Schicke RK Int J Health Serv; 1973; 3(2):223-36. PubMed ID: 4197751 [No Abstract] [Full Text] [Related]
4. Data-mining law struck down. Supreme court sides with drug companies in Vermont ruling. Carlson J Mod Healthc; 2011 Jun; 41(26):8-9. PubMed ID: 21853604 [No Abstract] [Full Text] [Related]
5. [Don't restrict the free right of prescription!]. Bågenholm EN Lakartidningen; 2002 Mar; 99(10):1093-4. PubMed ID: 12024787 [No Abstract] [Full Text] [Related]
6. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Gross DJ; Ratner J; Perez J; Glavin SL Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794 [TBL] [Abstract][Full Text] [Related]
7. [Sense and nonsense of post-authorization surveillance]. de Mey C Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347 [No Abstract] [Full Text] [Related]
8. The off-label debate: a threat to the future of cancer care. Mortenson LE Cancer Invest; 1991; 9(5):597-9. PubMed ID: 1933492 [No Abstract] [Full Text] [Related]
9. Unintended effects of a cost-containment policy: results of a natural experiment in Germany. Schöffski O; Graf von der Schulenburg JM Soc Sci Med; 1997 Nov; 45(10):1537-9. PubMed ID: 9351143 [TBL] [Abstract][Full Text] [Related]
10. Implications of the Australian guidelines for the United States. Freund DA; Evans D; Henry D; Dittus R Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641 [No Abstract] [Full Text] [Related]
11. DUR programs: current trends and future directions. Wertheimer AI; Kralewski J Am Pharm; 1993 Feb; NS33(2):37-42. PubMed ID: 8456744 [No Abstract] [Full Text] [Related]
12. The pills that ate your profits. Meyer H Hosp Health Netw; 1998 Feb; 72(3):18-22. PubMed ID: 9483145 [TBL] [Abstract][Full Text] [Related]
13. Examining the impact of Part D on nursing home residents. Hudson N Find Brief; 2010 May; 13(4):1-3. PubMed ID: 21121179 [TBL] [Abstract][Full Text] [Related]
14. Merck's statin first to receive over-the-counter status. Sheridan C Nat Rev Drug Discov; 2004 Jul; 3(7):542-3. PubMed ID: 15272493 [No Abstract] [Full Text] [Related]
15. Regulating manufacturer-affiliated communication in the information age. Schulman KA; Abernethy DR; Rathore SS; Woosley RL Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664 [No Abstract] [Full Text] [Related]
16. The 26th Albany Rx survey: Tylenol with Codeine leads the way. DeNuzzo RV Med Mark Media; 1982 Apr; 17(4):36, 38, 40 passim. PubMed ID: 10255306 [No Abstract] [Full Text] [Related]
17. Prescription drugs: issues of cost, coverage, and quality. Copeland C EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445 [TBL] [Abstract][Full Text] [Related]